Journal of Clinical Medicine, Volume 14, Issue 24
2025 December-2 - 357 articles
Cover Story: Acute myeloid leukemia (AML) and myelodysplastic neoplasms (MDS) are clonal hematopoietic malignancies in which molecular profiling is now central to diagnosis and management. Targeted next-generation sequencing (NGS) panels have become the standard of care, enabling rapid and sensitive detection of recurrent mutations, structural variants, and gene fusions. NGS findings are embedded in WHO 2022, ICC, ELN, and IPSS-M frameworks, refining prognostic models, guiding therapy, and enabling the assessment of measurable residual disease (MRD). However, accurate interpretation requires robust bioinformatic pipelines, quality metrics, and awareness of technical limits. We provide a practical and accessible overview of NGS technology and its applications, with specific indications for the interpretation of NGS reports in AML and MDS. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.